922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas
M Forster, J Sacco, A Kong, G Wheeler… - Annals of …, 2020 - annalsofoncology.org
Background Patients with R/M SCC have low response rates to second line therapies,
including PD-1 inhibitors nivolumab and pembrolizumab, representing an area of unmet …
including PD-1 inhibitors nivolumab and pembrolizumab, representing an area of unmet …
922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas
M Forster, R Metcalf, J Sacco, A Kong… - Annals of Oncology …, 2020 - europepmc.org
Background Patients with R/M SCC have low response rates to second line therapies,
including PD-1 inhibitors nivolumab and pembrolizumab, representing an area of unmet …
including PD-1 inhibitors nivolumab and pembrolizumab, representing an area of unmet …
EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas
M Forster, R Metcalf, J Sacco, A Kong, G Wheeler… - 2020 - christie.openrepository.com
Background: Patients with R/M SCC have low response rates to second line therapies,
including PD-1 inhibitors nivolumab and pembrolizumab, representing an area of unmet …
including PD-1 inhibitors nivolumab and pembrolizumab, representing an area of unmet …
922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas
M Forster, R Metcalf, J Sacco, A Kong… - Annals of …, 2020 - ncbi.nlm.nih.gov
Background Patients with R/M SCC have low response rates to second line therapies,
including PD-1 inhibitors nivolumab and pembrolizumab, representing an area of unmet …
including PD-1 inhibitors nivolumab and pembrolizumab, representing an area of unmet …